title: The alpha-glucosidase inhibitor acarbose reduces the net electronegative charge of low-density lipoprotein in patients with newly diagnosed type 2 diabetes.
abstract: BACKGROUND
  Several epidemiological studies have shown that postprandial hyperglycemia is associated with an increased risk of cardiovascular disease (CVD). The present study was conducted in order to compare the effects of acarbose and glimepiride treatment on serum lipoprotein profiles in patients with type 2 diabetes.
  
  
  METHODS
  A total of 37 patients with newly diagnosed type 2 diabetes were studied. The patients were assigned randomly to treatment for 12 weeks with either acarbose (n=13, 100 mg x 3/day, group A), glimepiride (n=13, 2 mg/day, group G) or diet only (n=11, group D). Lipid and lipoprotein profiles before and after each treatment were evaluated.
  
  
  RESULTS
  A significant reduction in the net electronegative charge of low-density lipoprotein (emLDL) was observed in group A (-1.8, P<0.01), whereas no significant change in emLDL was observed in groups G and D. In group A, small VLDL and very small LDL levels were also decreased significantly (P<0.05). The change in emLDL levels correlated significantly with changes in very small LDL (r=0.751, P<0.01) and oxidized LDL levels (r=0.623, P<0.05).
  
  
  CONCLUSIONS
  These results suggest that measurement of serum emLDL may be a sensitive and clinically useful marker for determining qualitative lipoprotein abnormalities in diabetes, and that acarbose treatment lowers CVD risk by decreasing production of emLDL.
authors.affiliation: Department of Endocrinology and Metabolism, Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Kyoto 602-8566, Japan. goji@koto.kpu-m.ac.jp
authors.forename: Goji
authors.initials: G
authors.lastname: Hasegawa
authors.forename: Shizuo
authors.initials: S
authors.lastname: Kajiyama
authors.forename: Toru
authors.initials: T
authors.lastname: Tanaka
authors.forename: Saeko
authors.initials: S
authors.lastname: Imai
authors.forename: Hana
authors.initials: H
authors.lastname: Kozai
authors.forename: Aya
authors.initials: A
authors.lastname: Fujinami
authors.forename: Mitsuhiro
authors.initials: M
authors.lastname: Ohta
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Obayashi
authors.forename: Hyohun
authors.initials: H
authors.lastname: Park
authors.forename: Koji
authors.initials: K
authors.lastname: Nakano
authors.forename: Muhei
authors.initials: M
authors.lastname: Tanaka
authors.forename: Emi
authors.initials: E
authors.lastname: Shiraishi
authors.forename: Michiaki
authors.initials: M
authors.lastname: Fukui
authors.forename: Toshikazu
authors.initials: T
authors.lastname: Yoshikawa
authors.forename: Naoto
authors.initials: N
authors.lastname: Nakamura
mesh_terms: D020909:Acarbose / Q000494:pharmacology* / Q000627:therapeutic use; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D008077:Lipoproteins, LDL / Q000378:metabolism*
chemical_list: D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D008077:Lipoproteins, LDL; D020909:Acarbose